peter block

Doc @YaleMed. Transplant-trained @NYULangone, GI-trained @YaleDigestive, and IM-trained @TJUHospital. Usually A/Ox2, views always my own.

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

It’s finally here‼️

🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖

Time to dive into the latest consensus on portal hypertension from @BavenoCoop

Enjoy! 😉

🔗 https://t.co/cZSckSc3zk

[Gastroenterology @AGA_Gastro]

1/ 💬 A new three-part commentary series in #Gastroenterology examines some of the most pressing questions in liver transplantation today.
⬇️ Join the conversation as experts share perspectives on where the field is now and where it may be headed next.
#Hepatology

[Elliot Tapper @ebtapper]

This month @HepCommJournal publishes a white paper on POCUS training in hepatology

https://t.co/tKm0APXUjv @JoseDebesMD @WRayKimMD @AASLDtweets

[Jose Debes MD PhD @JoseDebesMD]

Thank you @US_FDA for giving at least some more tools to fight HDV!
@AASLDtweets @AASLDPresident @HepBFoundation

[Kavish Patidar @KavishPatidar11]

Real-world use of terlipressin for HRS-AKI in the US here.

➡️16-center (n=243 patients)

🔹 Overall Response: 55.1%
🔹 HRS Reversal: 30.9%
🔹 90-day mortality: 40.5%

➡️50% Extended Criteria (presence of ≥1 FDA warning) mostly 2/2 ACLF grade 3.

https://t.co/LTZqBjdTkK

[The Lancet @TheLancet]

Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new treatments.

A new study found that GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity: https://t.co/MhUTBf9G7h

[Abhishek Yadav @aby10GI]

Grateful and humbled to share that our study from PGI Chandigarh 🇮🇳has been published in BMJ Gut 🇬🇧
This milestone wouldn’t have been possible without the constant guidance, support, and mentorship of my respected teachers and guides.
@HMandavdhare @drvishal82 @DrJimilShah

[Kohilan Gananandan @KGananandan]

Great fun writing this article on landmark papers in decomp cirrhosis and CSPH.

Thanks @ReibergerThomas and Prof Tsochatzis for being co-authors and @FrontGastro_BMJ for publishing! Check out 👇

https://t.co/ORSSFBCUup

@EASLedu @BASLedu @BSGTrainees @AASLDtweets #livertwitter

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New research - Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review & meta-analysis

https://t.co/i8zreww8kM

#LiverTwitter #MedTwitter #IDTwitter

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New research - Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis

https://t.co/WvZjvh8nKH

#LiverTwitter #IDTwitter #MedTwitter

[NEJM @NEJM]

Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results and Research Summary: https://t.co/PpNO71uhur

[Gastroenterology @AGA_Gastro]

💉 The March Editor's Essential Reading is a commentary on the importance of the #HepatitisB vaccine. Read the article here: https://t.co/Q7he3ehIrn

[Elliot Tapper @ebtapper]

Rifaximin reduces the risk of readmissions for hepatic encephalopathy. One of the clearest cases where RCT-based effect sizes are reproducible in trials

https://t.co/cQicZ4ucqk
@ArunJesudian @HepCommJournal

[HEPATOLOGY Journal @HEP_Journal]

Artículo Original

Niveles más altos de HBsAg se asocian con un desarrollo más tardío de carcinoma hepatocelular en pacientes en fase de tolerancia inmunitaria

Tseng et al.
#LiverX
https://t.co/w4pEnKUn0W

[HEPATOLOGY Journal @HEP_Journal]

Original Article

Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection

Hui et al.
#LiverX
https://t.co/YGDQYiXGZ5

[Elliot Tapper @ebtapper]

This paper is so cool!

Lovers of liver and the heart please unite and read
https://t.co/j5roPnJNba

[Elliot Tapper @ebtapper]

When used wisely albumin can help patients with cirrhosis says the best meta-analysis on this in @HepCommJournal

https://t.co/wKMh5zoXHw

But these trials are small and misuse - SO COMMON - outside of trials is harmful. How to thread the needle?

[HEPATOLOGY Journal @HEP_Journal]

Original Article

Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021

Danpanichkul et al.
#LiverX
https://t.co/c71QFNYrVT

[American Gastroenterological Association (AGA) @AmerGastroAssn]

Best practices for managing ascites, volume overload & hyponatremia in cirrhosis.
Our new CPU in @AGA_Gastro shares 1️⃣3️⃣ evidence-based tips to support clinical decision-making.
Read more here: https://t.co/VT2rL72eIJ
@orman_md @BrettEFortuneMD @AsraniSumeet
#GITwitter

[HEPATOLOGY Journal @HEP_Journal]

Original Article

Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials

Shi et al.
#LiverX
https://t.co/LqInZetqQf